Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: Solid Biosciences Inc. will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on September 18 at 10:20 am ET. Additionally, MBX Biosciences, Inc. has priced its IPO at $16.00 per share, aiming to raise $163.2 million from the sale of 10.2 million shares.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
